Risky business.
作者信息
Jones Roger
出版信息
Br J Gen Pract. 2014 Apr;64(621):163. doi: 10.3399/bjgp14X677707.
Abstract
摘要
相似文献
1
Risky business.
Br J Gen Pract. 2014 Apr;64(621):163. doi: 10.3399/bjgp14X677707.
2
International variation in medication prescription rates among elderly patients with inflammatory bowel disease.
J Crohns Colitis. 2013 Dec;7(11):878-89. doi: 10.1016/j.crohns.2012.09.001. Epub 2012 Sep 25.
3
[Endoscopic capsule: position paper of the Catalan Society of Gastroenterology].
Gastroenterol Hepatol. 2011 Oct;34(8):573-83. doi: 10.1016/j.gastrohep.2011.05.002. Epub 2011 Aug 19.
4
Mesalamine-Associated Sinus Bradycardia.
Am J Ther. 2019 Nov/Dec;26(6):e763-e764. doi: 10.1097/MJT.0000000000000932.
5
Assessment and initial management of acute undifferentiated fever in tropical and subtropical regions.
BMJ. 2018 Nov 29;363:k4766. doi: 10.1136/bmj.k4766.
6
[Galenic aspects and therapy of chronic inflammatory bowel diseases. Introduction].
Med Klin (Munich). 1999 Feb 15;94 Suppl 1:3.
7
Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors.
Ann Pharmacother. 2017 Feb;51(2):163-178. doi: 10.1177/1060028016672035. Epub 2016 Oct 4.
8
5-aminosalicylates in inflammatory bowel disease--the more the merrier?
Eur J Gastroenterol Hepatol. 1995 Nov;7(11):1017-9. doi: 10.1097/00042737-199511000-00001.
9
Hypersensitivity to 5-ASA suppositories.
Dig Dis Sci. 1999 Dec;44(12):2552-3. doi: 10.1023/a:1026611827653.
10
Mesalamine for refractory celiac disease: an old medicine for a new disease.
J Clin Gastroenterol. 2011 Jan;45(1):1-3. doi: 10.1097/MCG.0b013e3181fb4535.
本文引用的文献
1
Developing a preliminary 'never event' list for general practice using consensus-building methods.
Br J Gen Pract. 2014 Mar;64(620):e159-67. doi: 10.3399/bjgp14X677536.
2
Clinical futures. Are as important to health policy as economic and social futures.
BMJ. 1998 Dec 5;317(7172):1542. doi: 10.1136/bmj.317.7172.1542.
Zotero 插件